Prosopagnosia
Introduction of Prosopagnosia
Prosopagnosia can be developed or acquired. Some of the most common causes of acquired prosopagnosia include destructive conditions such as posterior cerebral artery stroke or hematoma. Developmental prosopagnosia (DP) is a cognitive disorder characterized by severe facial recognition defects without any known impairments, neurological diseases, or low-level visual or intellectual impairments. It is estimated that about 2% of adults and children have experienced DP or “face blindness”. This situation can seriously affect daily life, and even produce devastating consequences, such as avoiding social interactions, interpersonal problems, damage to careers, and even depression.
Prosopagnosia is Related to Cortical Damage
Damage to specific areas of the cerebral cortex leads to many high visual processing disorders, which have specific roles in processing certain aspects of vision. Face recognition is supported by the collaboration of multiple facial reaction areas in the brain. A neural model is proposed based on the normal face recognition brain area, the occipital face area (OFA), the fuzzy face area (FFA), and the face-selective posterior superior temporal sulcus (pSTS) are used as the core face network (CFN), and the rest of the face response area serves as an extended surface network (EFN). By exploring the resting functional connection (FC) between the facial response areas of patients with DPs, we found that these interrupted FCs are related to DP's behavioral defects in face recognition.
Fig.1 FMRI diagram of DPs and normal core face network (CFN). (Zhao, 2018)
NMDA Receptor Play a Role in Prosopagnosia
Anti-N-methyl-D-aspartate (NMDA) receptor encephalitis is an autoimmune disease that exhibits various neurological symptoms, including behavioral changes, memory deficits, seizures, and static form prosopagnosia. The patient can recognize the form of moving objects, but not the form of stationary objects. NMDA receptor encephalitis involves antibodies against the GluN1 subunit of the NMDA receptor. These antibodies may cause the binding, capping, and cross-connection of NMDA receptors, leading to the internalization of neuronal membrane surface receptors, and the dysfunction of signal transmission mediated by glutamine synapses. Therefore, drug mediated signaling pathways related to NMDA receptors may be available regulatory pathways for the treatment of prosopagnosia.
Fig.2 Cognitive network affected by NMDAR dysfunction. (Dalmau, 2016)
Creative Biolabs has many reliable protein/peptides, neurotransmitter, and antibody products in the field of neuroscience,it may be a useful reagent for your research on prosopagnosia and related neuroencephalitis.
Product Name | Biological Activity | Target | Cat.NO. |
ACBC [NMDA Agonist] | Agonist | NMDA Receptor | MOD2005ZP369 |
Amantadine hydrochloride [NMDA Antagonist] | Antagonist | NMDA Receptor | MOD2005ZP370 |
Mouse Anti-GluN1/NR1 Monoclonal Antibody (NS308-48) | WB / IHC / ICC / IF | GRIN1/NMDAR1 | NAB2007FY693 |
Recombinant Human GRIN1 Protein (N-GST) | ELISA / SDS-PAGE / WB | GRIN1/NMDAR1 | NPR2008PZ1542 |
If you need any customized services or products, please feel free to contact us.
References
- Zhao, Y.; et al. The neural network for face recognition: Insights from an fMRI study on developmental prosopagnosia. NeuroImage. 2018, 169: 151-161.
- Dalmau, J. NMDA receptor encephalitis and other antibody-mediated disorders of the synapse: The 2016 Cotzias Lecture. Neurology. 2016, 87(23): 2471-2482.
- NeuroMab™ Anti-Tau Antibody(NRP-0422-P1686) (Cat#: NRP-0422-P1686)
- NeuroMab™ Anti-ApoC3 BBB Shuttle Antibody(NRZP-1022-ZP3505) (Cat#: NRZP-1022-ZP3505)
- iNeuMab™ Mouse Anti-LRP1 Monoclonal Antibody (CBP3363) (Cat#: NAB-0720-Z6479)
- NeuroMab™ Anti-SEZ6 Antibody(NRP-0422-P517) (Cat#: NRP-0422-P517)
- iNeuMab™ Rabbit Anti-Alpha-synuclein (CBP1631) (Cat#: NAB-08-PZ079)
- NeuroMab™ Anti-TNFα BBB Shuttle Antibody(NRZP-1022-ZP4105) (Cat#: NRZP-1022-ZP4105)
- NeuroMab™ Anti-CD32b Antibody(NRP-0422-P1803) (Cat#: NRP-0422-P1803)
- NeuroMab™ Anti-Alpha Synuclein BBB Shuttle Antibody(NRZP-1022-ZP4050) (Cat#: NRZP-1022-ZP4050)
- Mouse Anti-Human α-Synuclein Phospho (Tyr39) (CBP3706) (Cat#: NAB201250LS)
- NeuroMab™ Anti-Tau Antibody(NRP-0422-P1760) (Cat#: NRP-0422-P1760)
- Mouse Retinal Ganglion Cell Line RGC-5 (Cat#: NCL2110P154)
- Human Glial (Oligodendrocytic) Hybrid Cell Line (MO3.13) (Cat#: NCL-2108P34)
- Mouse Microglia Cell Line BV-2, Immortalized (Cat#: NCL2110P153)
- Human Astrocytes (Cat#: NCC20-9PZ01)
- Immortalized Human Cerebral Microvascular Endothelial Cells (Cat#: NCL-2108-P020)
- Green Fluorescent Tau SH-SY5Y cell Line (Cat#: NCL2110P219)
- Mouse Midbrain Dopaminergic Neuron Cell MN9D (Cat#: NCL2110P059)
- Human Blood Brain Barrier Model (Cat#: NCL-2103-P187)
- Human Dental Pulp Stem Cells (Cat#: NRZP-1122-ZP113)
- Mouse Retinal Ganglion Cells (Cat#: NCL2110P145)
- Human Tau Aggregation Kit (Cat#: NRP-0322-P2173)
- Human GFAP ELISA Kit [Colorimetric] (Cat#: NPP2011ZP383)
- Alpha Synuclein Aggregation Kit (Cat#: NRZP-1122-ZP15)
- Amyloid beta 1-42 Kit (Cat#: NRP-0322-P2170)
- Beta Amyloid (1-40), Aggregation Kit (Cat#: NRZP-0323-ZP199)
- Beta Amyloid (1-42), Aggregation Kit (Cat#: NRZP-0323-ZP200)
- Human Poly ADP ribose polymerase,PARP Assay Kit (Cat#: NRZP-1122-ZP62)
- Alpha-Synuclein Aggregation Assay Kit (Cat#: NRZP-1122-ZP37)
- AAV2/9-hEF1a-fDIO-eNpHR 3.0-mCherry-WPRE-pA (Cat#: NTA-2012-ZP78)
- pAAV-hSyn-DIO-XCaMP-R-WPRE (Cat#: NTA-2012AD-P508)
- pAAV-syn-jGCaMP8s-WPRE (Cat#: NTA-2106-P063)
- Dextran-FITC (Cat#: NTA-2011-ZP110)
- pAAV-syn-FLEX-jGCaMP8s-WPRE (Cat#: NTA-2106-P066)
- pAAV-syn-jGCaMP8f-WPRE (Cat#: NTA-2106-P061)
- AAV2 Full Capsids, Reference Standards (Cat#: NTC2101070CR)
- Dextran, NHS Activated, 40 kDa (Cat#: NRZP-0722-ZP124)
- VSV-eGFP (Cat#: NTA-2011-ZP20)
- pAAV-syn-jGCaMP8m-WPRE (Cat#: NTA-2106-P062)
- ABCA1 Antisense Oligonucleotide (NV-2106-P27) (Cat#: NV-2106-P27)
- Lenti of Human TAR DNA binding protein (TARDBP) (NM_007375) ORF clone, mGFP Tagged (Cat#: NEP-0521-R0832)
- Human huntingtin-associated protein 1 (HAP1) transcript variant 2 (NM_177977) ORF clone, Myc-DDK Tagged (Cat#: NEP-0521-R0676)
- Human huntingtin (HTT) (NM_002111) ORF clone, Myc-DDK Tagged (Cat#: NEP-0521-R0497)
- Lenti of Mouse synuclein, alpha (Snca) transcript variant (NM_001042451) ORF clone, mGFP Tagged (Cat#: NEP-0521-R0864)
- Human superoxide dismutase 3, extracellular (SOD3) (NM_003102) ORF clone, Untagged (Cat#: NEP-0521-R0808)
- Human superoxide dismutase 1, soluble (SOD1) (NM_000454) ORF clone, TurboGFP Tagged (Cat#: NEP-0521-R0748)
- App Rat amyloid beta (A4) precursor protein (App)(NM_019288) ORF clone, Untagged (Cat#: NEP-0421-R0053)
- Mouse SOD1 shRNA Silencing Adenovirus (Cat#: NV-2106-P14)
- Mouse Parkinson disease (autosomal recessive, early onset) 7 (Park7) (NM_020569) clone, Untagged (Cat#: NEP-0621-R0133)
- NeuroBiologics™ Mouse Cerebrospinal Fluid (Cat#: NRZP-0822-ZP497)
- NeuroBiologics™ Pig Cerebrospinal Fluid (Cat#: NRZP-0822-ZP498)
- NeuroBiologics™ Monkey Cerebrospinal Fluid (Cat#: NRZP-0822-ZP495)
- NeuroBiologics™ Rat Cerebrospinal Fluid (Cat#: NRZP-0822-ZP496)
- NeuroBiologics™ Human Cerebrospinal Fluid (Cat#: NRZP-0822-ZP491)
- NeuroPro™ Anti-GDNF BBB Shuttle Protein (Cat#: NRZP-0423-ZP500)
- NeuroPro™ Anti-SGSH BBB Shuttle Protein (Cat#: NRZP-0423-ZP505)
- NeuroPro™ Anti-PON1 BBB Shuttle Protein (Cat#: NRZP-0423-ZP507)
- NeuroPro™ Anti-Erythropoietin BBB Shuttle Protein (Cat#: NRZP-0423-ZP499)
- NeuroPro™ Anti-EPO BBB Shuttle Protein (Cat#: NRZP-0423-ZP508)
- NeuroPro™ Anti-NAGLU BBB Shuttle Protein (Cat#: NRZP-0423-ZP506)
- NeuroPro™ Anti-ASA BBB Shuttle Protein (Cat#: NRZP-0423-ZP504)
- NeuroPro™ Anti-TNFR BBB Shuttle Protein (Cat#: NRZP-0423-ZP501)
- NeuroPro™ Anti-IDUA BBB Shuttle Protein (Cat#: NRZP-0423-ZP498)
- NeuroPro™ Anti-TNFR BBB Shuttle Protein (Cat#: NRZP-0423-ZP510)